Efficacy of imitinib combined with pegylated interferon in the treatment of chronic hepatitis B patients with low viremia and its effect on liver function and hepatitis B virus RNA level in mononuclear cells
Wu Yingfeng
Zhu Shuhua
Zhou Jie
Abstract：Objective To explore the efficacy of emitinofovir(TMF)combined with pegylated interferon α-2b(peg-IFNα-2b)on the treatment of patients with chronic hepatitis B(CHB)accompanied by low-level viremia(LLV),as well as its impacts on liver function and mononuclear cell hepatitis B virus(PBMC HBV)RNA levels.Method A total of 120 CHB patients with LLV who were treated in our hospital from February 2021 to February 2023 were prospectively selected as the study subjects.They were divided into a combination group and a control group according to the random number table method,with 60 cases in each group.The control group received TMF treatment,while the combination group received TMF combined with peg-IFN treatment,and both groups were treated for 24 weeks.The clinical efficacy of the two groups after treatment was compared.The changes in liver function indicators[alanine aminotransferase(ALT),aspartate aminotransferase(AST),and liver stiffness measurement(LSM)],hepatitis B surface antigen(HBsAg),E antigen(HBeAg),hepatitis B virus gene(HBV-DNA),and PBMC HBV RNA levels before and after treatment were compared between the two groups.The adverse reactions during the treatment period were also compared.Results After treatment,the total effective rate of the combination group(92.67%)was higher than that of the control group(81.67%)(χ2=5.783,P<0.05).The differences in HBsAg,HBeAg,PBMC HBV RNA,ALT,AST,and LSM levels before and after treatment in the combination group were higher than those in the control group(t=16.517,2.471,7.931,9.469,7.718,10.145,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(χ2=0.196,P>0.05).Conclusions TMF combined with peg-IFNα-2b can more effectively improve the clinical efficacy of CHB patients with LLV,improve liver function,reduce the PBMC HBV RNA level,and effectively inhibit the progression of the disease.
Keywords：Tenofovir AmibufenamidePegylated interferon α-2bChronic hepatitis BLow-level viremiaPeripheral blood mononuclear cellLiver function
Publication Date：2025-02-27
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 85-88 )